AstraZeneca's First-in-Class Complement Factor D Inhibitor Danicopan Receives FDA Approval for PNH with Extravascular Hemolysis

Previously, Apellis' C3 cyclic peptide inhibitor and Novartis' Factor B inhibitor achieved success in succession and outperformed the C5 antibody. The success and approval of CFD+C5 combination therapy will help AstraZeneca further consolidate its position in the complement field, also demonstrating the clinical value of simultaneously blocking downstream C5 and the alternative complement pathway.